You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

12 Results
Drug
Other Name(s): Votrient®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Dec 2024
Drug
Other Name(s): Iressa®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Mar 2025
Drug
Other Name(s): Pomalyst®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Apr 2025
Drug
Other Name(s): Iclusig®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Aug 2023
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    pazopanib - For first-line treatment of advanced or metastatic renal cell carcinoma of clear cell histology in patients with good performance status (ECOG 0-1), with specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pazopanib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2024
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    gefitinib - First-line monotherapy in locally advanced (not amenable to curative therapy) or metastatic NSCLC patients who have activating mutations of EGFR-TK, with specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
gefitinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2021
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Myeloid (CML)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    ponatinib - For the treatment of Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia, according to specific clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
ponatinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2023
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL)
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    ponatinib - For the treatment of Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), according to specific clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
ponatinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2023
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Myeloid (AML)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    gilteritinib - Relapsed or Refractory FLT3-mutated acute myeloid leukemia
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
gilteritinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2022
Drug
Other Name(s): Xospata®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jul 2023
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    osimertinib - In combination with pemetrexed and platinum-based chemotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC), based on criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pemetrexed,
osimertinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2025
Drug
Other Name(s): Ibrance™
Quick Link(s):
Drug Monograph, Patient Info Sheet
Updated
Oct 2025